statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analysts Have Conflicting Sentiments on These Healthcare Companies: Astellas Pharma (OtherALPMF) and Verona Pharma (VRNA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Astellas Pharma (ALPMF Research Report) and Verona Pharma...

Verona Pharma's Options Frenzy: What You Need to Know

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product

The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales.
read more...

17,800 Shares in Verona Pharma plc (NASDAQ:VRNA) Purchased by PFG Investments LLC

PFG Investments LLC bought a new stake in Verona Pharma plc (NASDAQ:VRNA  Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The...

Verona Pharma (NASDAQ:VRNA) Stock Price Down 7.6%

Verona Pharma plc (NASDAQ:VRNA  Get Free Report) shares fell 7.6% during mid-day trading on Thursday . The company traded as low as $15.42 and last traded at $15.42. 80,327 shares changed...

Verona Pharma (VRNA, $16.73) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 7, 2024

This is a Bearish indicator signaling VRNA's price could decline from here. Traders may explore shorting the stock or put options...

Verona Pharma plc (VRNA, $16.73) entered Downtrend as Momentum indicator drops below 0 level on Mar 07, 2024

This indicator may be signaling that VRNA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

HC Wainwright Reiterates "Buy" Rating for Verona Pharma (NASDAQ:VRNA)

HC Wainwright restated their buy rating on shares of Verona Pharma (NASDAQ:VRNA  Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $32.00 target...

Verona Pharma (VRNA, $16.82) Stochastic Oscillator left the oversold zone on March 06, 2024

This is a signal that VRNA's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Verona Pharma plc (VRNA, $16.97) entered Downtrend as Momentum indicator drops below 0 level on Mar 05, 2024

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Volume	617,894.00
52-Wk High	$23.72
52-Wk Low	$11.39

VRNA Verona Pharma Plc American Depositary

About

Feed

News

Sentiment

Earnings

Fundamentals